Validation study including over 2,700 patients confirms the prognostic performance of Stratipath Breast
The study, which was recently published in Breast Cancer Research and conducted by Karolinska Institutet in Stockholm, validates the prognostic performance of Stratipath Breast in a large retrospective cohort of over 2,700 patients from two independent clinical sites.
Stratipath Secures Spot on Prestigious 33-List of Top Innovative Tech Companies for Third Consecutive Year
Stratipath has been recognized as one of the Gold Companies on NyTeknik – First with news about technology and IT. and Affärsvärlden’s prestigious 33-list – for the maximum three consecutive years!
